PROC News and Press, Procaps Group S.A. From 09/05/23

2023-09-05 13:19:05 ET Procaps Group S.A. (PROC) Q2 2023 Earnings Call Transcript September 5, 2023, 11:00 AM ET Company Participants Melissa Angelini - IR Director Ruben Minski - CEO Patricio Vargas - CFO Conference Call Participants Kemp Doliver - B...

Net Revenues Increased 7% in 1H23 Year-over-Year, on a Constant Currency Basis, Signaling Positive Performance of Rx Products Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated international healthcare and pharmaceutical ser...

AeroVironment Inc. (AVAV) is expected to report $0.4 for Q1 2024 Jeronimo Martins - S.G.P.S., S.A. ADR (JRONY) is expected to report $0.74 for Q2 2023 TuSimple Holdings Inc. (TSP) is expected to report $-0.63 for Q2 2023 CVR Medical Corp (CRRVF) is expected to report for quarter end 2...

Procaps Group S.A. (PROC) is expected to report $0.06 for Q2 2023

Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023. The Compan...

Introduces New High Temperature Gummy Technology Platform that Solves Formulation and Distribution Challenges Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, announced...

2023-06-06 01:14:16 ET Procaps Group press release ( NASDAQ: PROC ): Q1 Revenue of $84M beats by $1M . On a constant currency basis, net revenues increased by 10%. Gross profit for 1Q23 totaled $46 million, with a 55% gross margin. Adjusted EBITDA reached $9 m...

MIAMI and BARRANQUILLA, Colombia, June 05, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated international healthcare and pharmaceutical services company, today announced its 1Q23 financial results. “We are executing on our ...

Constant Currency Net Revenues Increased 7% Year-over-Year in 2022, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Portfolio Preliminary Results for 1Q23 Show a Significant Rebound from 4Q22 Performance, Company Expects to Reach at Least High S...

MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Fu...